BRAX.CN - Braxia Scientific Corp.

Braxia Scientific Corp.

700 Bay Street
Suite 1903
Toronto, ON M5G 1Z6
Canada
416-762-2138
https://braxiascientific.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Roger S. McIntyre	Chairman & CEO	300k	N/A	N/A
Mr. Stephen R. Brooks	Chief Financial Officer	180k	N/A	N/A
Mr. Peter Rizakos	Chief Legal Officer & Gen. Counsel	175k	N/A	N/A
Dr. Joshua Rosenblat	Chief Medical & Scientific Officer	N/A	N/A	N/A
Mr. Jason Wolkove	Chief Information Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform. Braxia Scientific Corp. is headquartered in Toronto, Ontario.

Corporate Governance

Braxia Scientific Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.